Atorvastatin in Myeloma
Sponsor
Bayside Health (Other)
Overall Status
Unknown status
CT.gov ID
NCT00164086
Collaborator
(none)
1
Study Details
Study Description
Brief Summary
The purpose of this trial is to study the effects of a medication already widely used to treat cardiovascular disease and diabetes, in reducing the progression of myeloma.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Study Design
Study Type:
Interventional
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- Myeloma in remission
Exclusion Criteria:
- Adverse events (AEs) to statin, already on a statin, or contraindication to statin
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Alfred Hospital | Melbourne | Victoria | Australia | 3181 |
Sponsors and Collaborators
- Bayside Health
Investigators
- Principal Investigator: Andrew Spencer, MBChB, FRACP, PhD, The Alfred
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00164086
Other Study ID Numbers:
- 7/04
First Posted:
Sep 14, 2005
Last Update Posted:
Oct 11, 2006
Last Verified:
Sep 1, 2005